Aardvark Therapeutics, Inc. (AARD) stock
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00+0.09 (+9.89%)
Close on Nov 19, 2026Market cap $21.88MP/E –Yield –
Aardvark Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Aardvark Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$54.27M. For fiscal 2025 it was -$54.27M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.27M | – |
| FY2024 | Dec 31, 2024 | -$18.20M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$16.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.96M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.20M | – |
See a number that looks wrong?